

# Nausea & Vomiting in advance cancer - Revisit

Dr ML Tsang, Wong Tai Sin Hospital

Nausea & vomiting are common symptoms in advance cancer, affecting between 40 – 70% of patients

## NAUSEA

Nausea is an unpleasant feeling of the need to vomit. It is often accompanied by autonomic symptoms – such as pallor, cold sweat, salivation, tachycardia, and diarrhea. It is usually associated with changes in gut motility patterns, especially gastric stasis. Gastric acid secretion is reduced & salivation increased. Nausea is usually more prolonged & more difficult to control than vomit.

## VOMITING

Vomiting is defined as forceful expulsion of the gastric contents via the mouth. It is commonly followed by lethargy & pronounced muscular weakness.

## ANATOMY & PHYSIOLOGY (FIG 1 &2)

Stress, anxiety & nausea from any cause induce delayed gastric emptying (via peripheral dopaminergic R on myenteric plexus). This effect is antagonized by the D2-receptor antagonists eg. Metoclopramide & domperidone. In GI tract, enterochromaffin cells in bowel wall is rich in 5HT, which is massively release in response to various stimuli: abdominal RT, chemotherapy & bowel distention and sensitizes the vagal nerve which terminate in CTZ.




Fig. 1. Major emetogenic pathways




Fig 2.

## MANAGEMENT OF NAUSEA & VOMITING

- Evaluation
- Explanation to patient & family
- Individualized treatment
- Supervision & monitoring
- Attention to Detail

EVALUATION – Identify the most likely cause(s)- (usually caused by several concurrent factors) through detailed history, physical examination, investigation (if appropriate).

### 1. Detailed History-

It is important to distinguish between vomiting & expectoration (by check the pH: gastric secretions – acidic; expectorate – alkaline). Try to evaluate nausea & vomiting separately. Find out the time of onset of symptoms e.g. coinciding with the patient starting morphine. Review drug regimen. Review pattern of vomiting –

- Diurnal variation, related to meal time
- Whether nausea is absent or persistent for prolonged periods after vomiting

Note the content of vomitus - **color** : coffee ground, bile, blood stained, undigested food; **odour** : faeculent. Search for factors which may affect or exacerbate the symptoms of N & V : pain & fear, anxiety, odours : e.g. from fungating wound.

### 2. Physical examination

### 3. Investigation if appropriate

#### 1. Common causes of Nausea & Vomiting in advance Cancer

- Metabolic - Hypercalcaemia, renal failure
- Toxic
- RT, Chemotherapy, infection or paraneoplastic phenomenon

- Brain metastases
- Psychosomatic factors – eg. Anxiety or fear
- Pain

## 2. Record the severity of symptoms

### 3. Correct reversible causes-

Potentially reversible causes & exacerbating factors should be treated when appropriate –eg. severe pain, infection, cough, hypercalcaemia, tense ascites

### 4. Non-drug treatments -General measures including:

- A calm, reassuring environment with fresh air
- Unpleasant odors should be minimized e.g. Colostomy, fungating tumour or decubitus ulcer
- Avoidance of exposure to foods known to precipitate N & V
- Avoidance of perfumes, odors of foods that may precipitate N & V
- Sour foods such as lemons & rinsing of mouth with weak lemon juice may reduce nausea
- Small portions, small snacks (esp. for pts with anorexia & early satiety)
- Distraction – talk, music , TV, radio & reading may be of assistance

### 5. Start drug treatment with an antiemetic if Steps 3 &4 will not give immediate relief

#### First-line antiemetics:

**Prokinetic antiemetic:** for gastritis, gastric stasis, functional bowel obstruction

Eg. Metoclopramide

**Antiemetic (act in CTZ):** for most chemical causes of vomiting eg. Morphine,

Eg. Haloperidol

**Antiemetic (act in VC) :** for mechanical bowel obstruction, - ICP, motion sickness

Eg cyclizine

■ **Do not prescribe a prokinetic drug & an anticholinergic drug concurrently**

■ **The final common pathway for prokinetic drugs is cholinergic**

■ **Anticholinergic drugs (include cyclizine) block their prokinetic action**

Table 1 Receptor site affinities of selected antiemetics

	Dopamine D <sup>2</sup> -antagonist	Histamine H <sup>1</sup> -antagonist	Acetylcholine (muscarinic) antagonist	5HT <sub>2</sub> antagonist	5HT <sub>3</sub> antagonist	5HT <sub>4</sub> antagonist
Metoclopramide	++	0	0	0	(+)	++
Domperidone	+++ <sup>a</sup>	0	0	0	0	0
Cisapride	0	0	0	0	0	+++
Ondansetron <sup>b</sup>	0	0	0	0	+++	0
Cyclizine	0	++	++	0	0	0
Hyoscine hydrobromide	0	0	+++	0	0	0
Haloperidol	+++	0	0	0	0	0
Prochlorperazine	++	+	0	0	0	0
Chlorpromazine	++	++	+	0	0	
Levomopromazine (methotrimeprazine)	++	+++	++	+++	0	

Pharmacological activity: 0 none or insignificant, + slight, ++ moderate, +++ marked.

a. Domperidone does not cross the blood-brain barrier and therefore does not cause extrapyramidal effects

b. Other 5HT<sub>3</sub> antagonists – e.g. granisetron and tropisetron – have comparable receptor affinity.

Pharmacological activity: 0 none or insignificant, + slight, ++ moderate, +++ marked.

a. Domperidone does not cross the blood brain barrier and therefore does not cause extrapyramidal effects

### **Important factors to consider when prescribing for N & V**

- Take account of the effects of antiemetics on GI motility
  - Prokinetic (metoclopramide, domperidone)
  - Antikinetic (anticholinergics, antihistaminic anticholinergics)
- Adjuvant use of antisecretory drugs (eg hyoscine butylbromide, octreotide)
- Use of corticosteroids
- Use of appropriate administration route that ensures delivery of the antiemetic to the site of action
- Appropriate treatment of psychological factors (counselling, benzodiazepines)
- Adverse effects of drugs
- Costs of drugs

### 6. Re-evaluate at regular intervals

- Optimise the dose of antiemetic every 24 hours
- Change the treatment if there is no improvement after 24 – 48 hours
- Add an appropriate 2<sup>nd</sup> antiemetic on a 24-48 hour trial basis (~ 1/3 of pts with N&V need >1 antiemetic for satisfactory control)

### **Explanation**

Explain the cause of N & V & discuss the treatment options with patient & the family  
Which in turn will enable the patient to maintain some element of control

### References

- 1) Nausea and vomiting in advance cancer – European Journal of Palliative Care, 1998;5(2):39-45
- 2) The management of nausea and vomiting in advance cancer – Internatinal Journal of Palliative Nursing, 2000 Jan, Vol 6 No1 P18 - 26